TRIM30C Inhibitors
TRIM30C inhibitors refer to a class of compounds that target the TRIM30C protein, a member of the tripartite motif (TRIM) family of proteins. TRIM proteins are characterized by the presence of a conserved domain structure that includes a RING finger domain, one or two B-box domains, and a coiled-coil region. These proteins are typically involved in various cellular processes, including ubiquitination, signal transduction, and regulation of gene expression. TRIM30C, specifically, is an E3 ubiquitin ligase that plays a role in tagging specific substrates for degradation via the ubiquitin-proteasome system. By inhibiting TRIM30C activity, researchers can alter protein homeostasis and other related cellular pathways. TRIM30C inhibitors are valuable in understanding the specific mechanisms by which this ubiquitin ligase modulates intracellular signaling cascades, particularly those involving protein turnover and degradation.
The structural design of TRIM30C inhibitors typically focuses on blocking the E3 ligase activity, which could involve interference with the catalytic RING domain or with the protein-protein interactions mediated by the coiled-coil region. A variety of small molecules, peptides, and other chemical modulators have been studied to achieve selective inhibition of TRIM30C. Structural studies, including X-ray crystallography and computational modeling, help researchers identify key binding sites within the TRIM30C structure to optimize inhibitory potency and specificity. Moreover, inhibition of TRIM30C provides insights into broader regulatory networks involving TRIM proteins, particularly in cell signaling and proteostasis. This approach also sheds light on the intricate balance of protein synthesis and degradation within the cellular environment, offering a better understanding of how TRIM30C contributes to these processes at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that directly targets the ubiquitin-proteasome system. By blocking proteasomal degradation, it may disrupt Trim30c-mediated ubiquitin protein ligase activity, impacting cellular processes reliant on ubiquitination and proteasomal degradation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 inhibits NEDD8-activating enzyme, preventing cullin neddylation and subsequent activation of Cullin-RING ubiquitin ligases. As Trim30c is predicted to be part of a ubiquitin ligase complex, MLN4924 may indirectly inhibit Trim30c's ubiquitin protein ligase activity by disrupting the neddylation process. | ||||||
MK-0752 | 471905-41-6 | sc-364534 sc-364534A | 10 mg 50 mg | $592.00 $1550.00 | ||
MK-0752 specifically targets I-kappaB kinase (IKK), a key player in NF-kappaB signaling. By inhibiting IKK, this compound may directly impede Trim30c-mediated positive regulation of I-kappaB kinase/NF-kappaB signaling, affecting downstream NF-kappaB transcription factor activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082 inhibits NF-kappaB activation by blocking I-kappaB phosphorylation and degradation. This compound may indirectly inhibit Trim30c's positive regulation of NF-kappaB transcription factor activity by disrupting the canonical NF-kappaB signaling pathway. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin is a topoisomerase I inhibitor that induces DNA damage. Indirectly, it may impact Trim30c's function by activating DNA damage responses, influencing cellular processes related to Trim30c's predicted involvement in the regulation of viral entry into host cells. | ||||||
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
Amlexanox inhibits IKKε/TBK1, key regulators of the non-canonical NF-kappaB pathway. By blocking this pathway, Amlexanox may indirectly modulate Trim30c's positive regulation of I-kappaB kinase/NF-kappaB signaling and impact cellular responses associated with NF-kappaB transcription factor activity. | ||||||
UNC2881 | 1493764-08-1 | sc-475257 | 5 mg | $290.00 | ||
UNC2881 is an inhibitor of Mer and Axl receptor tyrosine kinases. As Trim30c is predicted to have protein kinase binding activity, this compound may indirectly affect Trim30c function by modulating specific protein kinases that interact with Trim30c, influencing its cellular activities. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
JSH-23 inhibits NF-kappaB nuclear translocation by interfering with I-kappaBα phosphorylation. This may indirectly impact Trim30c's positive regulation of NF-kappaB transcription factor activity by preventing the release of NF-kappaB from its inhibitory complex, affecting downstream signaling pathways. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX795 is an inhibitor of TBK1 and IKKε, key regulators of the non-canonical NF-kappaB pathway. Indirectly, it may modulate Trim30c's function by affecting the activities of these kinases, influencing cellular responses associated with Trim30c's predicted role in the regulation of viral entry into host cells. | ||||||
ML 120B Dihydrochloride | 783348-36-7 (free base) | sc-487759 | 5 mg | $380.00 | ||
MLN120B inhibits IkappaB kinase (IKK) and IKK-related kinases. By targeting these kinases, it may indirectly impact Trim30c's positive regulation of I-kappaB kinase/NF-kappaB signaling, affecting downstream NF-kappaB transcription factor activity and associated cellular responses. | ||||||